




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5





FIG. 6



*Prior mirvetuximab soravansine treatment

Median no. of cycles: 6.5 (100 mg/m²) and 7.0+ (120 mg/m²)

FIG. 7




FIG. 8




FIG. 9




FIG. 10A




FIG. 10B




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 11E




FIG. 11F




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 12E